Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Axil Capital is a venture capital firm based in Tokyo, Japan, specializing in biomedical and healthcare technology investments. Founded in 2017 as a spin-off from Mizuho Securities, the firm has established itself as a key player in the life sciences sector. Axil Capital aims to create synergies between the biotechnology ecosystems in Japan and globally, focusing on building companies that deliver long-term value and sustainable returns to investors.
Currently, Axil Capital manages a diverse portfolio and has made significant strides in the life sciences sector. The firm invests across various stages, including pre-seed, seed, Series A, Series B, Series C, and growth equity. Its geographic focus is primarily on Asia, with a strong emphasis on Japan. The firm has been actively expanding its portfolio, demonstrating a commitment to fostering innovation in healthcare technology.
Axil Capital focuses on investments in the life sciences sector, covering a wide range of areas including biopharmaceuticals, platform technologies, medical devices, digital health, and healthcare services. The firm targets both early-stage ventures and late-stage crossover rounds, aiming to diversify its portfolio across various stages of development. This approach allows Axil Capital to capitalize on emerging trends and technologies within the healthcare landscape.
The firm seeks to invest in companies that demonstrate strong potential for growth and innovation. Axil Capital looks for founders who are passionate about their projects and possess a clear vision for their companies. The investment strategy emphasizes creating long-term value, which aligns with the firm’s goal of providing sustainable returns to its investors.
Axil Capital has built a notable portfolio of companies within the life sciences sector. Key portfolio companies include:
This diverse portfolio reflects Axil Capital's commitment to fostering innovation and supporting companies that are poised to make significant impacts in the healthcare sector.
Frederick Schoen - Managing Partner: Frederick has extensive experience in venture capital and investment banking, having previously worked at Mizuho Securities. He specializes in life sciences investments and has led numerous successful funding rounds.
Hiroshi Utsunomiya - Partner: Hiroshi brings a wealth of knowledge in healthcare investments, with a background in both finance and biotechnology. He has been instrumental in building Axil Capital's portfolio.
Yoshitake Maeda - Venture Partner: Yoshitake has a strong track record in the biotech sector, focusing on strategic partnerships and business development for portfolio companies.
Kaito Usui, Ph.D. - Senior Principal: Kaito holds a Ph.D. in biomedical engineering and has experience in both research and venture capital, providing valuable insights into technology-driven investments.
Jun Baek, Ph.D., MBA - Principal: Jun combines his scientific background with business acumen, focusing on identifying and evaluating investment opportunities in the life sciences.
Kenji Maekubo, M.S. - Principal: Kenji has a strong background in healthcare technology and investment analysis, contributing to the firm's strategic decision-making.
Akio Kiyota, Ph.D. - Principal: Akio specializes in medical devices and has extensive experience in product development and commercialization within the healthcare sector.
Submit your pitch through their website's contact form at [URL]. Ensure your proposal aligns with their focus on life sciences and healthcare technology.
In recent months, Axil Capital has made significant investments in the life sciences sector, including notable companies such as Elixiron Immunotherapeutics and LinqMed. These investments reflect the firm's commitment to fostering innovation and supporting the growth of healthcare technology.
As of October 2023, Axil Capital continues to expand its portfolio, actively seeking new opportunities in the biotech and healthcare sectors. The firm emphasizes creating synergies between Japan's biotechnology ecosystem and global markets, positioning itself as a key player in the industry.
What are Axil Capital's investment criteria?
Axil Capital invests in the life sciences sector, focusing on biopharmaceuticals, medical devices, and digital health. The firm targets both early-stage and late-stage investments, seeking companies with strong growth potential and innovative solutions.
How can startups apply or pitch to Axil Capital?
Startups interested in pitching to Axil Capital should prepare a detailed presentation that outlines their business model, market opportunity, and competitive advantages. Direct outreach through their website is recommended for initial contact.
What makes Axil Capital different from other venture capital firms?
Axil Capital's unique focus on the life sciences sector, combined with its commitment to creating synergies between Japan's biotechnology ecosystem and global markets, sets it apart. The firm emphasizes long-term value creation and sustainable returns.
What is the geographic scope of Axil Capital's investments?
Axil Capital primarily focuses on investments in Asia, particularly Japan, but also seeks opportunities that connect with global markets in the life sciences sector.
What is Axil Capital's approach to post-investment involvement?
Axil Capital actively supports its portfolio companies through mentorship, operational guidance, and strategic advice. The firm aims to foster growth and innovation within its investments.
What is the typical check size for investments made by Axil Capital?
Axil Capital invests across various stages, including pre-seed, seed, Series A, Series B, Series C, and growth equity, with check sizes varying accordingly to align with the specific needs of each company.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.